Phospho-c-Kit (Y703) Polyclonal Antibody, 100µg, (ATB-P0658)

Description

Background:

This gene encodes the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. This protein is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.

Product datasheet:

Overview
Product Description	Phospho-c-Kit (Y703) Polyclonal Antibody, 100µg, (ATB-P0658)
Image
Species Reactivities	Human,Mouse
Immunogen	Synthesized peptide derived from human c-Kit around the phosphorylation site of Y703.
Properties
Form	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage Instructions	-20°C/1 year
Clonality	Polyclonal

References:

1. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. Qin YZ, et al. Leuk Res, 2014 Dec. PMID 25449688
2. The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation. Szatkowski D, et al. Acta Haematol, 2015. PMID 25247397
3. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. de Melo Campos P, et al. Leuk Res, 2014 Oct. PMID 25139846
4. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Jin Y, et al. Cancer Lett, 2014 Oct 10. PMID 25088577
5. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis. Balci TB, et al. Br J Haematol, 2014 Oct. PMID 24989799
6. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.
   Yarden Y., Kuang W.-J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J., Chen E., Schlessinger J., Francke U., Ullrich A.
   EMBO J. 6:3341-3351(1987) [PubMed] [Europe PMC] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY. Tissue: Fetal brain and Term placenta.
7. Organization and nucleotide sequence of the human KIT (mast/stem cell growth factor receptor) proto-oncogene.
   Giebel L.B., Strunk K.M., Holmes S.A., Spritz R.A.
   Oncogene 7:2207-2217(1992) [PubMed] [Europe PMC] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1 AND 2).
8. Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes.
   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V., Hu W.X., Galibert F.
   Genomics 39:216-226(1997) [PubMed] [Europe PMC] Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA].
9. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.
   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.
   Arthritis Res. Ther. 10:R73-R73(2008) [PubMed] [Europe PMC] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
10. Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate.
    Neumann I., Foell J.L., Bremer M., Volkmer I., Korholz D., Burdach S., Staege M.S.
    Pediatr. Blood Cancer 55:464-470(2010) [PubMed] [Europe PMC] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, INDUCTION.